Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from Rhabdomyosarcoma human cells treated with Ipatasertib or Miransertib.

ABSTRACT: Expression data from Rhabdomyosarcoma human cells treated with Ipatasertib or Miransertib.

PROVIDER: PRJNA1115079 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data from Rhabdomyosarcoma human cells treated with Ipatasertib or Miransertib.

Project description:The AKT inhibitors Ipatasertib and Miransertib show differential anti-tumor activity against RMS. We use microarrays to compare the transcriptomic effects of each AKT inhibitor in RMS and to identify the diffential gene signature of each drug in RMS.

2025-07-16 | GSE268191 | GEO

PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor Ipatasertib in Rhabdomyosarcoma

Project description:Rhabdomyosarcoma (RMS) is marked by a myogenesis differentiation blockade, and while the AKT/mTOR pathway is universally activated, its pharmacological inhibition has shown limited success. This study stems from an effort to understand the failure to translate preclinical findings to clinical application. Here, we evaluated the activity of two pan-AKT inhibitors: Ipatasertib, an ATP-competitive inhibitor, and Miransertib, an allosteric AKT inhibitor. In vitro and in vivo efficacy assessment was conducted in RMS cell lines and fusion-positive/negative patient-derived xenografts (PDX). Unlike Miransertib, Ipatasertib showed significant antitumor activity against a subset of RMS. Besides AKT, the other kinase target of Ipatasertib, but not of Miransertib, is PRKG1, a cGMP-dependent protein kinase that shares the ATP binding pocket with AKT. The role of PRKG1 in RMS was investigated in PRKG1-depleted RMS cells and in xenograft models by transcriptomic approaches. PRKG1 silencing in RMS cells reduced tumor formation in xenograft models and induced a differentiated myogenic transcriptome. RMS showed higher PRKG1 expression compared to any other developmental cancer, akin to fetal skeletal muscle. Importantly, PRKG1 expression in RMS correlates with mesodermal transcriptional signature and enhanced sensitivity to Ipatasertib, regardless of the fusion oncogene status. The antitumor activity of Ipatasertib is dose-dependent, reaching an effective intra-tumor concentration when administered at 25 mg/kg daily. This study unveils the role of PRKG1 in myogenesis and highlights the potential of PRKG1 as a clinical biomarker for Ipatasertib therapy in RMS.

2025-07-16 | PXD064262 | Pride

SUM149PT cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)

Project description:SUM149PT cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat).

2024-01-01 | GSE205730 | GEO

MDA-MB-468 cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)

Project description:MDA-MB-468 cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat).

2024-01-01 | GSE205729 | GEO

SUM149PT cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)

Project description:SUM149PT cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)

| PRJNA847252 | ENA

SKBR3/HER2+ Breast Cancer Cellular Response to Lapatinib and Ipatasertib Kinase Inhibitors

Project description:To explore the broader impact of kinase inhibitors on breast cancer cells, SKBR3/HER2+ cells were treated with two small molecule drugs, i.e., Lapatinib (10 uM) - a Tyr kinase inhibitor, and Ipatasertib (1 uM) - a Ser/Thr kinase inhibitor. Serum-starved cells (24 h) were exposed for 36 h to Lapatinib/EGF or a combination of Lapatinib/Ipatasertib/EGF. EGF - only stimulated cells were used as control. The EGF concentration was 10 nM throughout all experiments. Proteomic profiles of nuclear and cytoplasmic cell fractions of treated vs non-treated cells were generated by nano-LC-MS/MS using an Orbitrap QE instrument.

2024-08-23 | PXD051094 | Pride

Transcriptomic analysis in 6 primary RMS tumors and their corresponding PDX.

Project description:Gene expression analysis of Rhabdomyosarcoma patient biopsies and their Patient derived xenograft tissues. Transcriptimic and Functional analysis correlated with in vivo Ipatasertib efficacy. PRKG1 mRNA levels in Rhabdomyosarcoma biopsies and PDX.

2025-07-16 | GSE268192 | GEO

Gene Expression in Human Rhabdomyosarcoma

Project description:Gene expression analysis identified unique transcriptional changes in rhabdomyosarcoma when compared with normal muscle. Our studies focused on a gene called VANGL2 that regulated growth and self-renewal in embryonal rhabdomyosarcoma.

2018-03-06 | GSE108022 | GEO

MDA-MB-468 cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)

Project description:MDA-MB-468 cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)

| PRJNA847253 | ENA

Gene Expression in Human Rhabdomyosarcoma

Project description:Gene Expression in Human Rhabdomyosarcoma

| PRJNA1115071 | ENA